Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya26956Research ArticleModern possibilities of HER2 positive breast cancer treatment (based on clinical trials)KolyadinaI Virinakolyadina@yandex.ruPoddubnayaI V-Department of Oncology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, MoscowN.N.Blokhin Russian Cancer Research Center (RCRC) (115478, Kashirskoe shosse, 24, Moscow, Russia)15122014164102009042020Copyright © 2014, Consilium Medicum2014This review includes the main steps of anti-HER2-therapy for breast cancer (BC). Up to 30% of breast tumors overexpress epidermal growth factor receptor HER2/neu, and this expression is correlated with poor prognosis and course of the disease. Determination of HER2-status in BC is mandatory for all stages, it is necessary to evaluate the prognosis and development of optimal therapeutic algorithm. The first targeted therapy developed in 1992 for the treatment of HER2-positive BC, has become trastuzumab (Herceptin). The unique mechanism of Herceptin (targeted blockade of HER-dependent signaling pathway, the blockade of the activation of PI3K and MAPK signaling pathway, activation of antibody-dependent cellular cytotoxicity, etc.) and high efficiency have significantly changed the prognosis of HER2-positive BC. The important role of 1-year adjuvant therapy with Herceptin has showed in large international trials (HERA, NSABP B-31, NCCTG 9831, BCIRG 006) for reducing the risk of recurrence (50%) and death (30%) in HER2-positive BC. Neoadjuvant chemotherapy with trastuzumab has studied in the large randomized trials (NOAH, GeparQuattro, GeparQuinto), which has been shown to benefit of Herceptin in the rate of pathological complete response and significant improvement of survival. The effectiveness of Herceptin in metastatic HER2-positive BC has showed in the large studies (M7701, HO648g, BCIRG 007, HERNATA, etc.) The advent of pertuzumab opened new perspectives for the treatment BC: pertuzumab inhibits HER2-receptor dimerization with other HER- receptors (HER1-3) and blocks the HER-mediated signaling pathways, activates of antibody-dependent cellular cytotoxicity. The combination of pertuzumab and trastuzumab blockade provides more HER2-mediated intracellular signaling pathways than either drug alone, which leads to a more pronounced anticancer response. In a large randomized study CLEOPATRA had shown unprecedented results of treatment of metastatic or recurrent BC: the increasing median of overall survival up to 56,5 months, regardless of age, race, the prior treatment, hormone receptor status and location of metastases. The benefit of pertuzumab has shown in old patients, patients with brain metastases, as well as a significant increase in progression-free survival. The new class of anti-HER2-agent - conjugates, appeared last time. Trastuzumab emtanzin (T-DM1) - the first conjugate the targeted monoclonal antibody trastuzumab, cytotoxic chemotherapy agent (DM1) and linker. Antitumor effect of T-DM1 sum of the effects of trastuzumab (targeted blockade of HER-dependent signaling pathway) and targeted delivery of high effective agent (DM1), which causes cell death by disrupting microtubule polymerization and cell cycle arrest. Efficiency T-DM1 has shown to increase disease-free survival, rate and duration of response and overall survival in patients with HER2-positive advanced BC pretreated with taxanes and Herceptin (EMILIA trial). Modern treatment options in HER2-positive BC perfectly combine high efficiency, safety and saved the quality of life.T-DM1breast cancerHER2-positive statusHerceptinadjuvant and neoadjuvant anti-HER2-therapypertuzumabT-DM1рак молочной железыHER2-положительный статусГерцептинадъювантная и неоадъювантная анти- HER2-терапияпертузумаб[Slamon D.J, Godolphin W, Jones L.A et al. Studies of the HER-2/neu proto - oncogene in human breast and ovarian cancer. Science 1989; 244 (4905): 707-12.][Slamon D.J, Clark G.M, Wong S.G et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177-82.][Goldhirsch A et al. Ann Oncol 2006; 17: 1722-76.][Кудайбергенова А.Г., Пожарисский К.М. Стандарты Коллегии американских патологов по обследованию больных раком молочной железы. Материалы большой конференции RUSSCO «Рак молочной железы», 22-24 января 2014 г.; с. 52-4.][Zurawska U, Baribeau D.A, Giilck S et al. Outcomes of her2-positive early - stage breast cancer in the trastuzumab era: a population - based study of Canadian patients. Curr Oncol 2013; 20 (6): e539-45.][Theriault R.L, Litton J.K, Mittendorf E.A et al. Age and survival estimates in patients who have node - negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011; 11 (5): 325-31.][Curigliano G, Viale G, Bagnardi V et al. Сlinical relevance of HER2-over - expression/amplification in patients with small tumor size and node - negative breast cancer. J Clin Oncol 2009; 27 (34): 5693-9.][HercepTest® PI. HercepTest staining interpretation (3rd ed.); http://www.dakousa.com][Mitchell M.S, Press M.F. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999; 26: 108-16.][Mehdi I, Monem A.A, Bahrani A.B et al. Breast cancer molecular subtypes in oman: correlation with age, histology, and stage distribution - analysis of 542 cases. Gulf J Oncolog 2014; 1 (15): 38-48.][Tamaki M, Kamio T, Kameoka S et al. The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. World J Surg Oncol 2013; 11: 293; http://doi:10.1186/1477-7819-11-293][Papouchado B.G, Myles J, Lloyd R.V et al. Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma: Comparison With FISH and Assessment of Interobserver Reproducibility. Am J Surgical Pathology 2010; 34 (6): 767-76.][Izumi Y, Xu L, Tomaso di E et al. Tumor biology: Herceptin acts as an anti - angiogenic cocktail. Nature 2002; 416: 279-80.][Имянитов Е.Н. Герцептин: механизм действия. Соврем. онкология. 2009; 3 (11): 9-14.][Mello de R.A, Vasconcelos de A, Ribeiro R.A et al. Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies. Recent Pat DNA Gene Seq 2012; 6 (1): 56-63.][Perez E.A, Romond E.H, Suman V.J et al. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; http://pii:JCO.2014.55.5730][Perez E.A, Romond E.H, Suman V.J et al. Four - year follow - up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29 (25): 3366-73.][Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14): 1273-83.][Goldhirsch A, Gelber R.D, Piccart-Gebhart M.J et al. Herceptin Adjuvant Study Team. 2 years vs. 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open - label, randomised controlled trial. Lancet 2013; 382 (9897): 1021-8.][Gianni L, Dafni U, Gelber R.D et al. Herceptin Adjuvant (HER) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow - up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-44.][Romond E.H et al. Proc SABCS 2012. Abstr. S5.][Rodrigues M.J, Wassermann J, Albiges L et al. Trastuzumab treatment in T1ab, node - negative, human epidermal growth factor receptor 2-overex - pressing breast carcinomas. J Clin Oncol 2010; 28 (28): e541-2.][Horio A, Fujita T, Hayashi H et al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node - negative breast cancers. Int J Clin Oncol 2012; 17 (2): 131-6.][Rom J, Schumacher C, Gluz O et all. Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers. Breast Care Basel 2013; 8 (3): 208-14.][Gonzalez-Angulo A.M, Litton J.K, Broglio K.R et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node - negative tumors 1 cm or smaller. J Clin Oncol 2009; 27 (34): 5700-6.][Rouanet P, Roger P, Rousseau E et al. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med 2014; 3 (1): 134-42.][Theriault R.L, Litton J.K, Mittendorf E.A et al. Age and survival estimates in patients who have node - negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011; 11 (5): 325-31.][Curigliano G, Viale G, Bagnardi V et al. Сlinical relevance of HER2 overexpression/amplification in patients with small tumor size and node - negative breast cancer. J Clin Oncol 2009; 27 (34): 5693-9.][Livi L, Meattini I, Saieva C et al. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node - negative breast cancer. Cancer 2012; 118 (13): 3236-43.][Journal of the National Comprehensive Cancer Network; http://www.nccn.org/JNCCN][NCCN breast cancer guidelines professionals; http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast][Senkus E, Kyriakides S, Penault-Llorca F et al. On behalf of the ESMO Guidelines Working Group Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2013; 0: 1-17.][Клинические рекомендации по профилактике, диагностике и лечению больных раком молочной железы. Ассоциация онкологов России. Коллектив авторов ИГ РОНЦ 2014; с. 1-46; www.oncology.ru][Gianni L, Eiermann W, Semiglazov V et all. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow - up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15 (6): 640-7.][Buzdar A.U, Suman V.J, Meric-Bernstam F et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab vs. paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (13): 1317-25.][Minckwitz von G, Rezai M, Loibl S et al. Capecitabine in addition to anthracycline and taxane - based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28 (12): 2015-23.][Untch M, Loibl S, Bischoff J et al. Lapatinib vs. trastuzumab in combination with neoadjuvant anthracycline - taxane - based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 2012; 13 (2): 135-44.][Extra J.M et al. Eur J Cancer 2004; 2 (Suppl. 3): 125. Abstr. 239.][Slamon D.J et al. N Engl J Med 2001; 334: 783-92.][Valero V, Forbes J, Pegram M.D et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first - line chemotherapy for patients with HER2- gene - amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29 (2): 149-56.][Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first - line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29 (3): 264-71.][Huang et al. Cancer Res 2010; 70: 1204-14.][Rowinsky E.K. Ann Rev Med 2004; 55: 433-57.][Swain S.M, Kim S.B, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double - blind, placebo - controlled, phase 3 study. Lancet Oncol 2013; 14 (6): 461-71.][Swain S, Kim S, Cortes J et al. ESMO 2014. Abstr. 350O_PR. Oral presentation 28.09.14.][Giordano Sh.H, Temin S, Kirshner J.J et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer. American Society of Clinical Oncology Clinical Practice Guideline; http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0948][Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd International consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014; 25: 1871-88.][Lewis Phillips G.D, Li G, Dugger D.L et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 2008; 68: 9280-90.][Junttila T.T, Li G, Parsons K et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128: 347-56.][Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2- positive advanced breast cancer. N Engl J Med 2012; 367 (19): 1783-91.][Krop I, Lin N, Blackwell K et al. Efficacy and safety of trastuzumab emtansine (T-DM1) vs. lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer and central nervous system metastases: Results from a retrospective exploratory analysis of EMILIA. SABCS 2013; P4-12-27.][Welslau M, Diéras V, Sohn J.H et al. Patient - reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) vs. capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014; 120 (5): 642-51.][Baselga J, Cortes J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic Breast Cancer. N Engl J Med 2012; 366: 109-19.]